Wajiga 2 Tijaabada Kiliinikada ee Retatrutide, Hormone-Qaybiyaha Agonist ee Saddex-geesoodka ah, ee Daaweynta Cayilka

Asalkii hore iyo Nakhshad Daraasadeed

Retatrutide (LY3437943) waa dawo cusub oo hal peptide ah oo firfircoonsaddex receptors isku mar: GIP, GLP-1, iyo glucagon. Si loo qiimeeyo waxtarkeeda iyo badbaadada shakhsiyaadka leh cayilka laakiin aan lahayn sonkorow, wejiga 2, randomized, double-indhon, tijaabada placebo-control ayaa la sameeyay (NCT04881760). Wadarta guud338 ka qaybgalayaashaoo leh BMI ≥30, ama ≥27 oo leh ugu yaraan hal miisaan oo miisaan laxiriira, ayaa la kala soocay si loo helo placebo ama retatrutide (1 mg, 4 mg oo leh laba jadwal titration, 8 mg oo leh laba jadwal titration, ama 12 mg) oo lagu maamulo hal mar todobaadkiiba cirbadeynta subcutaneous ee toddobaadyada 48. Thedhamaadka aasaasiga ahwuxuu ahaa boqolkiiba isbeddelka miisaanka jidhka ee toddobaadyada 24, oo leh dhibcaha ugu dambeeya oo ay ku jiraan isbeddelka miisaanka 48 toddobaadyada iyo heerarka dhimista miisaanka (≥5%, ≥10%, ≥15%).

Natiijooyinka Muhiimka ah

• 24 usbuuc: Afar-jibaaranaha ugu yar micnaheedu waa boqolkiiba isbeddelka miisaanka jidhka marka loo eego gundhigga

  • Placebo: -1.6%

  • 1 mg: -7.2%

  • 4 mg (lagu daray): -12.9%

  • 8 mg (lagu daray): -17.3%

  • 12 mg: -17.5%

• 48 toddobaadIsbeddelka boqolkiiba miisaanka jidhka ayaa ahaa

  • Placebo: -2.1%

  • 1 mg: -8.7%

  • 4 mg (lagu daray): -17.1%

  • 8 mg (lagu daray): -22.8%

  • 12 mg: -24.2%

Usbuucyada 48, saamiga ka qaybgalayaasha ee gaadhay heerar miisaan dhimis caafimaad oo macne leh ayaa soo jiidatay:

• ≥5% miisaan lumis: 27% leh placebo vs. 92-100% ee kooxaha firfircoon

• ≥10%: 9% oo leh placebo vs. 73-93% ee kooxaha firfircoon

• ≥15%: 2% oo leh placebo vs. 55-83% ee kooxaha firfircoon

Kooxda 12 mg, ilaa26% kaqeybgalayaashu waxay lumiyeen ≥30% miisaankooda aasaasiga ah, baaxadda miisaanka dhimista oo u dhiganta qalliinka bariatric.

Badbaadada
Dhacdooyinka xunxun ee ugu caansan waxay ahaayeen caloosha iyo mindhicirka (lallabbo, matag, shuban), guud ahaan dhexdhexaad ilaa dhexdhexaad ah oo la xidhiidha qiyaasta. Qiyaasaha bilowga hoose (2 mg titration) ayaa hoos u dhigay dhacdooyinkan. Kor u kaca qiyaasta la xiriirta garaaca wadnaha ayaa la arkay, isagoo sare u kacay usbuuca 24, ka dibna hoos u dhacay. Heerarka joojinta waxay udhaxeeyeen 6-16% dhamaan kooxaha firfircoon, xoogaa ka sareeya placebo.

Gabagabadii
Dadka qaangaarka ah ee leh buurnaanta aan lahayn sonkorow, retatrutide subcutaneous toddobaadle ah ayaa la soo saaraa 48 toddobaadhoos u dhac weyn oo ku-tiirsanaanta miisaanka jirka(ilaa ~ 24% macnaheedu waa luminta qiyaasta ugu sarreysa), oo ay la socoto hagaajinta calaamadaha wadnaha. Dhacdooyinka xun-xun ee mindhicirku waxay ahaayeen kuwo soo noqnoqda laakiin la maarayn karo titration. Natiijooyinka wejiga 2 waxay soo jeedinayaan retatrutide inay matali karto bartilmaameed cusub oo daweynta buurnaanta, iyadoo la sugayo xaqiijinta tijaabooyinka wejiga 3 ee ballaaran, muddada dheer.